The incidence of end-stage renal disease (ESRD) among Canadian First Nations people is 2.5-4 times greater than among the non-First Nations population 123 and the most common cause is diabetic nephropathy. The earliest indicator of diabetic renal disease is microalbuminuria 45678910, which appears 5-10 years prior to the onset of overt proteinuria. Proteinuria is a sign of more advanced renal disease and is a precursor to renal failure 11. Importantly, albuminuria is a strong and independent predictor of cardiovascular and all cause mortality 12. Additionally, the impact of renal disease on health care costs and quality of life for patients and their caregivers is substantial 13141516. Blood pressure and glucose control among those with diabetes and/or chronic kidney disease, with either medication and/or lifestyle changes have shown to be effective in preventing progression to advanced renal disease 171819. Therefore screening for albuminuria in high risk populations may be one component of an effective community-based renal disease prevention strategy.

While the excess burden of diabetes among First Nations populations compared to the general Canadian population is well established 20, research on diabetes-related kidney disease among Canadian First Nations populations is more limited. A retrospective population-based study from Saskatchewan for the years 1981-90 revealed that among those with diabetes, the rate of ESRD in First Nation people was 7 times greater than among non-First Nation people 2. The prevalence of microalbuminuria among a sample of 601 First Nation residents in northern Saskatchewan was 24% among those with diabetes, and 9% among those without 21. Non-diabetic diseases, such as glomerulonephritis, that can lead to ESRD and which can present with albuminuria and hematuria are also significantly increased in First Nation people 3. According to the Canadian Diabetes Association Clinical Practice Guidelines, First Nations adults with at least one risk factor should be screened for diabetes every 1-2 years and those with type 2 diabetes should be screened for albuminuria at diagnosis and annually thereafter 22. Despite these recommendations and the increased burden of diabetic and non-diabetic renal disease, few population-based screening studies for albuminuria among Canadian First Nation populations have been performed. The study community reported in this article has a high prevalence of ESRD (5%), diabetes (29%) and impaired fasting glucose (7%) 23. Thus, the community is at high risk for diabetic renal complications. Therefore the purpose of this paper is to determine the prevalence and determinants of albuminuria in a Canadian First Nation population, and to begin planning for secondary prevention strategies.

The data for this paper are from a previously described larger screening study for diabetes and diabetes complications 23 conducted in 2003 among adult members of the Sandy Bay First Nation, located about 200 km northwest of Winnipeg, Manitoba, Canada, with year round road access. Its population in December 2001 was 2,968, of which 52% were under the age of 18. Inclusion criteria were: non-pregnant, community member, and 18 years and older. A total of 483 community members participated; 36% of all eligible adults (n = 1356). That is, there were 1356 eligible adults in the community, according to the inclusion criteria, and 483 chose to participate. Estimates of albuminuria were obtained on the 468 participants who had completed all components of the study, which included anthropometrics (height, weight, and waist and hip circumferences); a demographic and health status questionnaire; fasting blood samples for glucose, A1c,and lipids; and random urine sample. Although albuminuria is not the best clinical tool to identify kidney disease, for an epidemiological screening study, albuminuria is an excellent predictor for ESRD, CVD, and all-cause mortality 12. This study was approved by the Health Research Ethics Board at the University of Manitoba.

The study sample was representative of the larger community for age, sex, education and employment status 23. That is, the sample had similar proportions of the previously listed characteristics as the study population. Nine subjects were ineligible due to incomplete data and 6 were excluded from the albuminuria analysis due to persistent hematuria, leaving 468 subjects for albuminuria analysis. Participants with persistent hematuria were excluded due to the inability to obtain an ACR and we could not determine the cause of the hematuria. These individuals were referred for clinical evaluation. However, most individuals whose first test was positive for hematuria were found not to be hematuric on subsequent tests and were included in analysis. The majority of these participants were women who were tested close to their menstrual period.

Demographic and health risk characteristics of the study population are described in Table 1. Both sexes were equally represented. The population was young and the mean age was similar for men and women (37 for men; 38 for women). Less than half the study sample had completed grade 9. The study population had high rates of cardiovascular risk factors; three-quarters of participants were current smokers, 43% had hypertension, 35% had diabetes or prediabetes and obesity was highly prevalent.

¹Data are reported as n (percentage), mean (standard deviation)^a or median (range)^b.

²Hypertension is defined as a blood pressure >140/90 mm Hg for those without diabetes, ≥130/80 mm Hg for those with diabetes, or a previous diagnosis with medications.

³Diabetes is defined as fasting glucose ≥7.0 mmol/L or previous diagnosis.

⁴Impaired fasting glucose is fasting glucose between 6.1 mmol/L and 6.9 mmol/L with no previous diagnosis of diabetes.

⁵Albuminuria is albumin:creatinine ratio >2.8 mg/mmol for women and >2.0 mg/mmol for men.

⁶Awareness of disease states refers to participant awareness.

Twenty-five percent of the sample returned for at least a second random urine test (Table 2). However, of those who had abnormal samples (ie. hematuria or proteinuria) on their first test, 79% returned for a second or third test. Albuminuria was present in 95/468 or 20% of participants. Twenty-five participants (5%) had proteinuria and 70 (15%) had microalbuminuria. In univariate analysis [OR (95% CI) p-value], age [1.039 (1.008, 1.072) p = 0.014], diabetes [11.474 (4.209, 31.279) p < 0.001], systolic blood pressure [1.039 (1.019, 1.061) p < 0.001], diastolic blood pressure [1.051 (1.018, 1.086) p = 0.002], fasting glucose [1.257 (1.155, 1.367) p < 0.001] and hypertension [4.390 (1.709, 11.277) p = 0.002] were associated with proteinuria. There was a non-significant trend for lower odds of proteinuria among females [0.428 (0.181, 1.012) p = 0.053]. BMI, ever smoker, and years diagnosed with diabetes were not associated with proteinuria. For all other analysis, those with proteinuria and microalbuminuria were combined for analysis due to small numbers and equivalence on the following characteristics: age, sex, smoking status and mean years smoked. However, the proportion of those with diabetes was greater among the proteinuria group compared to the microalbuminuria group. Eighty percent (20/25) of those with proteinuria had diabetes.

^aMicroalbuminuria was defined as no positive dipstick reading for protein and at least one test with ACR >2.8 mg/mmol for women and >2.0 mg/mmol for men.

^bIndividuals with dipstick positive proteinuria (>1 g/L) or those with ACR in the macroalbuminuria of proteinuria range (≥30 mg/mmol) on at least one sample were considered to have proteinuria.

Participants with and without albuminuria are compared in Table 3. Those with albuminuria were older (p < 0.001) and albuminuria prevalence progressively increased with age (Figure 1). Men were more likely to have albuminuria than women (p = 0.01). Interestingly, those with albuminuria were less likely to report ever having smoked (p = 0.007). However, neither years of smoking nor pack-years smoked were significantly different between groups. Participants with albuminuria were more likely to be hypertensive by any measure. Seventy percent (70%) of those with albuminuria had hypertension compared with 36% of those without albuminuria (p < 0.0001). In this regard, mean blood pressures were significantly higher in the group with albuminuria compared to those without. Target blood pressure in those with albuminuria is generally recommended to be <130/80 mm Hg, however, this was achieved in only 34% of those with albuminuria.

Data are reported as n (percentage), mean (standard deviation)^a, median (range)^b.

¹Hypertension is defined as a previous diagnosis of hypertension or blood pressure ≥140/90 mm Hg.

²Blood pressure ≥130/80 mm Hg includes only participants with previous diagnosis of diabetes or hypertension.

³Diabetes is defined as on oral hypoglycemics, self declared diabetes or has a fasting glucose ≥7.0 mmol/L.

⁴Dysglycemia is defined as previous diagnosis of diabetes or a fasting plasma glucose ≥6.1 mmol/L.

⁵Hematuria was a positive dipstick for hemoglobin.

Participants with albuminuria were significantly heavier and had a higher BMI (Figure 2). This increased weight and BMI may be related to the greater proportion of participants in the albuminuric group with diabetes and impaired fasting glucose. Fasting glucose was also higher among those with albuminuria compared to those without (p < 0.001). While almost 60% of those with any degree of albuminuria had diabetes, 42% of those with diabetes were albuminuric.

Odds ratios and 95% CI are listed in Table 4 for both univariate and multivariate logistic regression. Backwards stepwise multivariate logistic regression was performed. Univariate analysis indicated the odds of having microalbuminuria increased 4% for each year increase in age. However, age was not significant in the final multivariate model. When both fasting glucose and years of diabetes were removed from the model and age was included, age became significant suggesting high multicolinearity between the diabetes and age (model not shown). Females were less likely to have microalbuminuria than males, which remained significant in the multivariate model. Smokers were less likely to have albuminuria than non-smokers and while smoking appeared protective in univariate analysis, it did not achieve significance in the multivariate model.

DM, diabetes mellitus; BMI, body mass index.

Those with diabetes were seven times more likely to have albuminuria than those without diabetes. In addition, for each mmol/L increase in average fasting glucose, albuminuria increased by 27% in the univariate model, and 20% when controlling for sex, years diagnosed with diabetes, systolic blood pressure and BMI. Length of time with diabetes was also a significant predictor of albuminuria and confirms the natural history of diabetic nephropathy. Systolic blood pressure was independently associated with albuminuria in the multivariate model and risk of albuminuria increased by 2% for every mm Hg increase in systolic blood pressure. Lastly, weight and BMI were both significant alone, but BMI was an independent predictor of albuminuria in the multivariate analysis, after accounting for average fasting glucose, gender, years diagnosed with diabetes mellitus and systolic blood pressure [1.042 (1.001, 1.085), p = 0.04].

In contrast to participants with diabetes and hypertension, very few with albuminuria were aware of their condition. Participant awareness of kidney disease increased with severity such that 17% of those with proteinuria were aware of kidney disease while awareness kidney disease in those with microalbuminuria was only 1% (Table 1).

High prevalence of diabetes and renal complications of diabetes (ESRD) have been previously described among Canadian First Nations people 12313233. Significant rates of renal complications (ESRD) among non-diabetic First Nations people are also seen 334. Microalbuminuria is well recognized as a significant precursor to either diabetic or non-diabetic renal disease, and has been described in both those with and without diabetes. In the current population-based study, albuminuria rates of 20% among the total population were as high as among other high-risk populations such as the Pima in the southwestern United States 4735. Among those with diabetes in our study, 42% had albuminuria, which is substantially greater than the prevalence among the general US population (28.8%) as described in the NHANES III study 36, and the 24% estimated in a Canadian First Nation population-based study in Saskatchewan 21. The present study prevalence is comparable to the American Pima and Zuni populations in which 47% and 52% of the diabetic population, respectively, had albuminuria 715.

The current study found female gender protective for albuminuria, independent of fasting glucose, years with diabetes, systolic blood pressure or BMI. This association was also found in the Strong Heart Study 37. This contrasts with the NHANES III and Pima Indian non-diabetic data, in which women had significantly more albuminuria than men 736. The NHANES III study, however, did not use the lower cut-off for ACR in males, as did the current study. A different ACR cut-off due to higher excreted creatinine in males has been supported by many investigators and is supported by the Canadian Diabetes Association Clinical Practice Guidelines 26383940, and may account for the differences between the NHANES and Pima Indian non-diabetic data and the current study. Furthermore, in the Pima diabetic population and the Zuni Indian population studies, no sex differences were seen 4735. Mortality rates among men with albuminuria tend to be higher than in women 41, and therefore the increased albuminuria among men in our study is concerning.

BMI was also independently related to increased prevalence of albuminuria in the study sample. Although increased BMI has been described as a risk factor for albuminuria and proteinuria 42 and high BMI is an issue among those of First Nations ancestry 434445, to our knowledge, BMI has not been previously described as an independent risk factor for microalbuminuria in the Canadian First Nations population.

While age has been found to be significantly associated with albuminuria 36, age was not included in our final multivariate model, likely due to high multicolinearity with duration of diabetes and diabetes itself. However, the average age of those with albuminuria increased by glycemic status (i.e., non-diabetes, IFG and diabetes). While by no means confirmatory, this suggests a possible difference in lead time. As albuminuria is a risk factor for diabetes 46, those younger individuals with dysglycemia and even without diabetes, may develop diabetes as they age.

Participant awareness of kidney disease in a First Nation community is reported here for the first time. Awareness of kidney disease within the study population was low compared to other disease states such as diabetes and hypertension. Awareness of kidney disease was also lower than that found among the general U.S. population where 24% of participants reported being aware of their kidney disease 29. Disease awareness is related to many factors at both the individual and systems levels. At the individual level, reported awareness of disease can be limited by patient understanding and denial; that is, although care providers may inform patients of their illness, patients may not integrate that information. Another factor affecting awareness is lack of screening or diagnostic testing on the part of health care providers, thereby preventing detection. At the systems level, access to physicians on the part of patients and suitable practice environments for physicians (i.e., access to and remuneration for diagnostic testing) can either enable or act as barriers to preventive practice. Factors influencing poor disease awareness among our study population could not be determined. Thus, further research is required to address the lower than anticipated awareness in this high-risk population.

The study is subject to limitations. The sample size is limited and was not randomly selected from the eligible population. However, our sample was representative of the eligible study population on demographic factors (i.e., age, sex, employment, education) and, as previously reported 23, was not over-represented by the ill or infirmed. In fact, only 38% of those known to have diabetes at the start of the study were participants. In addition, only three out of 10 individuals with previous amputations participated in the study, and none of the 15 individuals with ESRD participated. Therefore, we are confident that our sample represents the larger community. However, the results may not be generalizable beyond the study population because we are not able to determine if the study population is representative of First Nations communities across Canada. Furthermore, the lack of availability of serum creatinine to further indicate severity of renal dysfunction is also a limitation. Lastly, those participants that had a normal ACR did not complete repeat testing.

Albuminuria is an important complication of diabetes and a risk factor for ESRD and cardiovascular disease. Identification of relevant risk factors is therefore an important activity that can assist in the development of targeted prevention efforts. Interestingly, we found the presence of significant numbers of people with microalbuminuria and hematuria without other risk factors, confirming the presence of non-diabetic renal disease. Further investigations should be focused on this group; first to help ascertain the cause of their hematuria or albuminuria, and second to intervene appropriately. Lack of awareness of early renal disease among study participants is a concern and efforts to understand the phenomenon and improve awareness will be undertaken in partnership with the community. Ongoing longitudinal follow-up of the individuals in this study would further our understanding of the significance of individual health determinants. In addition, further follow-up would give important information about the natural history of albuminuria in this population. The response to treatment and community intervention strategies could also be assessed.

ACE: Angiotensin-converting enzyme; ACR: Albumin-creatinine ratio; ARB: Angiotensin receptor blocker; BMI: Body mass index; ESRD: End-stage renal disease.

The authors declare that they have no competing interests.

JZ conducted data analysis, interpretation, and preparation of the manuscript. KY is the principal investigator and was involved in the conception and design of the study, analysis and has reviewed this manuscript for intellectual content. NDR assisted in data analysis and preparation of the manuscript for publication. JR is the Director of the health centre in the community and was involved in the conception and design of the study. SB contributed to the conception and design of the study as well as acquisition of the data, analysis and preparation of the manuscript. All authors read and approved the final manuscript.